Pseudolaric acid B suppresses T lymphocyte activation through inhibition of NF-κB signaling pathway and p38 phosphorylation

Journal of Cellular Biochemistry

Volumn 108, Issue 1, 2009, Pages 87-95

  Li, Ting ^a   Wong, Vincent Kam Wai ^a   Xiao, Qin Yi ^a   Yuen, Fan Wong ^a   Zhou, Hua ^a   Liu, Liang ^a  

^a HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

Author keywords

CD25; NF B; p38; Pseudolaric acid B; T lymphocyte activation

Indexed keywords

CD69 ANTIGEN; I KAPPA B ALPHA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; IONOMYCIN; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCLONAL ANTIBODY CD28; OKT 3; PHORBOL 13 ACETATE 12 MYRISTATE; PSEUDOLARIC ACID B; TRANSCRIPTION FACTOR RELA;

ANTIGEN EXPRESSION; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; T LYMPHOCYTE ACTIVATION;

CELL PROLIFERATION; DITERPENES; HUMANS; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTE ACTIVATION; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

PSEUDOLARIX KAEMPFERI;

EID: 69249115789     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22230     Document Type: Article

References (37)

1. Calixto JB, Otuki MF, Santos AR. 2003. Anti-inflammatory compounds of plant origin. Part I. Action on arachidonic acid pathway, nitric oxide and nuclear factor kappa B (NF-kappaB). Planta Med 69:973-983.
2. Camargo JF, Quinones MP, Mummidi S, Srinivas S, Gaitan AA, Begum K, Jimenez F, VanCompernolle S, Unutmaz D, Ahuja SS, Ahuja SK. 2009. CCR5 expression levels influence NFAT translocation, IL-2 production, and subsequent signaling events during T lymphocyte activation. J Immunol 182:171-182.
3. Caruso A, Licenziati S, Corulli M, Canaris AD, De Francesco MA, Fiorentini S, Peroni L, Fallacara F, Dima F, Balsari A, Turano A. 1997. Flow cytometric analysis of activation markers on stimulated T cells and their correlation with cell proliferation. Cytometry 27:71-76.
4. Diehn M, Alizadeh AA, Rando OJ, Liu CL, Stankunas K, Botstein D, Crabtree GR, Brown PO. 2002. Genomic expression programs and the integration of the CD28 costimulatory signal in T cell activation. Proc Natl Acad Sci USA 99:11796-11801.
5. Dong C, Davis RJ, Flavell RA. 2002. MAP kinases in the immune response. Annu Rev Immunol 20:55-72.
6. Epinat JC, Gilmore TD. 1999. Diverse agents act at multiple levels to inhibit the Rel/NF-kappaB signal transduction pathway. Oncogene 18:6896-6909.
7. Gately MK, Desai BB, Wolitzky AG, Quinn PM, Dwyer CM, Podlaski FJ, Familletti PC, Sinigaglia F, Chizonnite R, Gubler U, Stern AS. 1991. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J Immunol 147:874-882.
8. Gerlier D, Thomasset N. 1986. Use of MTT colorimetric assay to measure cell activation. J Immunol Methods 94:57-63.
9. Ghittoni R, Patrussi L, Pirozzi K, Pellegrini M, Lazzerini PE, Capecchi PL, Pasini FL, Baldari CT. 2005. Simvastatin inhibits T-cell activation by selectively impairing the function of Ras superfamily GTPases. FASEB J 19:605-607.
10. Ghosh S, Karin M. 2002. Missing pieces in the NF-kappaB puzzle. Cell 109(Suppl): S81-S96.
11. Gilmore TD. 2006. Introduction to NF-kappaB: Players, pathways, perspectives. Oncogene 25:6680-6684.
12. Gilmore TD, Herscovitch M. 2006. Inhibitors of NF-kappaB signaling: 785 and counting. Oncogene 25:6887-6899.
13. Hayden MS, West AP, Ghosh S. 2006. NF-kappaB and the immune response. Oncogene 25:6758-6780.
14. Ho LJ, Juan TY, Chao P, Wu WL, Chang DM, Chang SY, Lai JH. 2004. Plant alkaloid tetrandrine downregulates IkappaBalpha kinases-IkappaBalpha-NF-kappaB signaling pathway in human peripheral blood T cell. Br J Pharmacol 143:919-927.
15. Kane LP, Lin J, Weiss A. 2002. It's all Rel-ative: NF-kappaB and CD28 costimulation of T-cell activation. Trends Immunol 23:413-420.
16. Kim HP, Imbert J, Leonard WJ. 2006. Both integrated and differential regulation of components of the IL-2/IL-2 receptor system. Cytokine Growth Factor Rev 17:349-366.
17. Koike T, Yamagishi H, Hatanaka Y, Fukushima A, Chang JW, Xia Y, Fields M, Chandler P, Iwashima M. 2003. A novel ERK-dependent signaling process that regulates interleukin-2 expression in a late phase of T cell activation. J Biol Chem 278:15685-15692.
18. Krummel MF, Allison JP. 1996. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 183:2533-2540.
19. Leung CY, Liu L, Wong RN, Zeng YY, Li M, Zhou H. 2005. Saikosaponin-d inhibits T cell activation through the modulation of PKCtheta, JNK, and NF-kappaB transcription factor. Biochem Biophys Res Commun 338:1920-1927.
20. Li Q, Verma IM. 2002. NF-kappaB regulation in the immune system. Nat Rev Immunol 2:725-734.
21. Li E, Clark AM, Hufford CD. 1995. Antifungal evaluation of pseudolaric acid B, a major constituent of Pseudolarix kaempferi. J Nat Prod 58:57-67.
22. Lin JX, Leonard WJ. 1997. Signaling from the IL-2 receptor to the nucleus. Cytokine Growth Factor Rev 8:313-332.
23. Liu Y, Shepherd EG, Nelin LD. 2007. MAPK phosphatases-regulating the immune response. Nat Rev Immunol 7:202-212.
24. Li-Weber M, Treiber MK, Giaisi M, Palfi K, Stephan N, Parg S, Krammer PH. 2005. Ultraviolet irradiation suppresses T cell activation via blocking TCR-mediated ERK and NF-kappa B signaling pathways. J Immunol 175:2132-2143.
25. Nguyen T, Wang R, Russell JH. 2000. IL-12 enhances IL-2 function by inducing CD25 expression through a p38 mitogen-activated protein kinase pathway. Eur J Immunol 30:1445-1452.
26. O'Neill LA. 2006. Targeting signal transduction as a strategy to treat inflammatory diseases. Nat Rev Drug Discov 5:549-563.
27. Pae HO, Oh GS, Choi BM, Chae SC, Kim YM, Chung KR, Chung HT. 2004. Carbon monoxide produced by heme oxygenase-1 suppresses T cell proliferation via inhibition of IL-2 production. J Immunol 172:4744-4751.
28. Pan DJ, Li ZL, Hu CQ, Chen K, Chang JJ, Lee KH. 1990. The cytotoxic principles of Pseudolarix kaempferi: Pseudolaric acid-A and -B and related derivatives. Planta Med 56:383-385.
29. Schett G, Tohidast-Akrad M, Smolen JS, Schmid BJ, Steiner CW, Bitzan P, Zenz P, Redlich K, Xu Q, Steiner G. 2000. Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum 43:2501-2512.
30. Tong YG, Zhang XW, Geng MY, Yue JM, Xin XL, Tian F, Shen X, Tong LJ, Li MH, Zhang C, Li WH, Lin LP, Ding J. 2006. Pseudolarix acid B, a new tubulin-binding agent, inhibits angiogenesis by interacting with a novel binding site on tubulin. Mol Pharmacol 69:1226-1233.
31. Weng NP, Levine BL, June CH, Hodes RJ. 1996. Regulated expression of telomerase activity in human T lymphocyte development and activation. J Exp Med 183:2471-2479.
32. Wong VK, Chiu P, Chung SS, Chow LM, Zhao YZ, Yang BB, Ko BC. 2005. Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo. Clin Cancer Res 11:6002-6011.
33. Wong VK, Zhou H, Cheung SS, Li T, Liu L. 2009. Mechanistic study of saikosaponin-d (Ssd) on suppression of murine T lymphocyte activation. J Cell Biochem 107:303-315.
34. Wu CC, Hsu SC, Shih HM, Lai MZ. 2003. Nuclear factor of activated T cells c is a target of p38 mitogen-activated protein kinase in T cells. Mol Cell Biol 23:6442-6454.
35. Wu WY, Guo HZ, Qu GQ, Han J, Guo DA. 2006. Mechanisms of pseudolaric Acid B-induced apoptosis in bel-7402 cell lines. Am J Chin Med 34:887-899.
36. Yoshizawa T, Hammaker D, Sweeney SE, Boyle DL, Firestein GS. 2008. Synoviocyte innate immune responses: I. Differential regulation of interferon responses and the JNK pathway by MAPK kinases. J Immunol 181:3252-3258.
37. Zhang J, Salojin KV, Gao JX, Cameron MJ, Bergerot I, Delovitch TL. 1999. p38 mitogen-activated protein kinase mediates signal integration of TCR/CD28 costimulation in primary murine T cells. J Immunol 162:3819-3829.